SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Clinical trial NCT05218148 · UNKNOWN

Trial details

NCT number: NCT05218148
Sponsor: Aiping Zhou
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Locally Advanced Solid Tumor Immunotherapy Sintilimab S-1 Oxaliplatin Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: 2022-04-01
Primary completion: 2024-10-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.